Fortress Biotech Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Fortress Biotech stock.
View analyst ratings for Fortress Biotech or view top-rated stocks.

Wall Street analysts have given Fortress Biotech a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Fortress Biotech wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Fortress Biotech is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Fortress Biotech.

Fortress Biotech, Inc. (NASDAQ:FBIO) issued its quarterly earnings results on Sunday, August, 15th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.15. The biopharmaceutical company earned $17.84 million during the quarter, compared to the consensus estimate of $13.82 million. Fortress Biotech had a negative trailing twelve-month return on equity of 15.34% and a negative net margin of 63.05%.
View Fortress Biotech's earnings history.

Fortress Biotech's stock was trading at $1.61 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, FBIO stock has increased by 108.1% and is now trading at $3.35.
View which stocks have been most impacted by COVID-19.

6 brokers have issued twelve-month price objectives for Fortress Biotech's shares. Their forecasts range from $5.00 to $21.00. On average, they expect Fortress Biotech's stock price to reach $10.60 in the next twelve months. This suggests a possible upside of 216.4% from the stock's current price.
View analysts' price targets for Fortress Biotech or view top-rated stocks among Wall Street analysts.

Some companies that are related to Fortress Biotech include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Novavax (NVAX), Repligen (RGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Exelixis (EXEL).
View all of FBIO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Novavax (NVAX), Advanced Micro Devices (AMD), OPKO Health (OPK), TG Therapeutics (TGTX), Vaxart (VXRT), NVIDIA (NVDA), Pfizer (PFE) and Dynavax Technologies (DVAX).

Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."

Fortress Biotech's stock is owned by a variety of retail and institutional investors. Top institutional investors include Nantahala Capital Management LLC (7.74%), Vanguard Group Inc. (5.52%), BlackRock Inc. (4.80%), Geode Capital Management LLC (1.35%), State Street Corp (1.28%) and Cpwm LLC (0.53%). Company insiders that own Fortress Biotech stock include Eric K Rowinsky, Lindsay A Md Rosenwald, Malcolm Hoenlein and Robyn Hunter.
View institutional ownership trends for Fortress Biotech.

FBIO stock was sold by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, BlackRock Inc., JPMorgan Chase & Co., Creative Planning, Goldman Sachs Group Inc., Man Group plc, Nuveen Asset Management LLC, and National Asset Management Inc.. Company insiders that have sold Fortress Biotech company stock in the last year include Eric K Rowinsky, and Robyn Hunter.
View insider buying and selling activity for Fortress Biotech or view top insider-selling stocks.

FBIO stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Vanguard Group Inc., Geode Capital Management LLC, State Street Corp, GSA Capital Partners LLP, Wells Fargo & Company MN, and Citadel Advisors LLC. Company insiders that have bought Fortress Biotech stock in the last two years include Lindsay A Md Rosenwald, and Malcolm Hoenlein.
View insider buying and selling activity for Fortress Biotech or or view top insider-buying stocks.

Shares of FBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FBIO stock can currently be purchased for approximately $3.35.

Fortress Biotech has a market capitalization of $338.56 million and generates $45.60 million in revenue each year. The biopharmaceutical company earns $-46,530,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis.

Fortress Biotech employs 111 workers across the globe.

The official website for Fortress Biotech is www.fortressbiotech.com.

Fortress Biotech is headquartered at 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014.

Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at (781) 652-4500 or via email at [email protected].